The miRNA Tools and Services Market is projected to grow from USD 540.92 million in 2025 to USD 2,432.31 million by 2034, at a CAGR of 18.23%. Growth is fueled by AI integration, personalized medicine, single-cell technologies, and multi-omics adoption. North America leads, with Asia-Pacific expanding fastest.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: MiRNA Tools and Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. MiRNA Tools and Services Market, by Product and Services
8.1.1 Research Tools
8.1.1.1. Market Revenue and Forecast
8.1.2. Services
8.1.2.1. Market Revenue and Forecast
9.1. MiRNA Tools and Services Market, by Technology
9.1.1. Extraction Tools
9.1.1.1. Market Revenue and Forecast
9.1.2. qRT-PCR
9.1.2.1. Market Revenue and Forecast
9.1.3. NGS
9.1.3.1. Market Revenue and Forecast
9.1.4. Microarray
9.1.4.1. Market Revenue and Forecast
9.1.5. Functional Analysis Tools
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. MiRNA Tools and Services Market, by End User
10.1.1. Research and Academic Institutes
10.1.1.1. Market Revenue and Forecast
10.1.2. IVD, Pharma and Biotech Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. CROs
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product and Services
11.1.2. Market Revenue and Forecast, by Technology
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product and Services
11.1.4.2. Market Revenue and Forecast, by Technology
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product and Services
11.1.5.2. Market Revenue and Forecast, by Technology
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product and Services
11.2.2. Market Revenue and Forecast, by Technology
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product and Services
11.2.4.2. Market Revenue and Forecast, by Technology
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product and Services
11.2.5.2. Market Revenue and Forecast, by Technology
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product and Services
11.2.6.2. Market Revenue and Forecast, by Technology
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product and Services
11.2.7.2. Market Revenue and Forecast, by Technology
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product and Services
11.3.2. Market Revenue and Forecast, by Technology
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product and Services
11.3.4.2. Market Revenue and Forecast, by Technology
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product and Services
11.3.5.2. Market Revenue and Forecast, by Technology
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product and Services
11.3.6.2. Market Revenue and Forecast, by Technology
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product and Services
11.3.7.2. Market Revenue and Forecast, by Technology
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product and Services
11.4.2. Market Revenue and Forecast, by Technology
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product and Services
11.4.4.2. Market Revenue and Forecast, by Technology
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product and Services
11.4.5.2. Market Revenue and Forecast, by Technology
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product and Services
11.4.6.2. Market Revenue and Forecast, by Technology
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product and Services
11.4.7.2. Market Revenue and Forecast, by Technology
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product and Services
11.5.2. Market Revenue and Forecast, by Technology
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product and Services
11.5.4.2. Market Revenue and Forecast, by Technology
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product and Services
11.5.5.2. Market Revenue and Forecast, by Technology
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Thermo Fisher Scientific
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Qiagen
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck KGaA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. PerkinElmer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Takara Bio Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. New England Biolabs
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. NanoString Technologies, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description